Skip to main content

Neuromuscular-Junction-on-a-Chip to study medication for Parkinson

Project description

Innovative chip-based device for the screening of Parkinson's disease medications

There is a growing interest in developing and investing in organ-on-a-chip devices from basic researchers and biotech and pharmaceutical companies. The lab-on-a-chip devices offer highly accessible systems for testing hypothesis-driven research ideas and screening of potential therapeutic compounds. Importantly, chip-based devices allow ultra-low-cost test solutions for medications. The goal of the EU-funded NMJ project is to develop a neuromuscular-junction-on-a-chip device tailored as α-synuclein-induced Parkinson's disease model. The objective is to introduce this chip-based device for testing Parkinson's disease medications proposed by Novartis and GlaxoSmithKline. The French microfluidic innovation centre Elvesys in Paris will provide expert support to the project.

Coordinator

ELVESYS
Net EU contribution
€ 184 707,84
Address
172 Rue De Charonne B2 2 Eme Etage
75011 Paris
France

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00